Related Experiment Video
Updated: Mar 26, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Current advances in targeted therapies for metastatic gastric cancer: improving patient care
Pedro Nazareth Aguiar1, Thiago Pimentel Muniz1, Raelson Rodrigues Miranda1
1Division of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
Abstract:
In this article, we review the literature on the current advances in targeted therapies for metastatic gastric cancer aimed at improving patient care. We conclude that the key to guiding targeted therapy is individual biomarkers, which are not completely elucidated. HER2 overexpression is the only predictive biomarker currently in use. Furthermore, it is necessary to understand that gastric tumors are heterogeneous; therefore, is impossible to evaluate a novel biological compound without evaluating personal biomarkers. The selection of patients who are able to receive each treatment is paramount for improving advanced gastric cancer survival and reducing unnecessary costs.
Insights
Individual biomarkers are crucial for guiding targeted therapy in metastatic gastric cancer. Personalized biomarker evaluation is essential for improving patient survival and reducing costs, as tumors are heterogeneous.
Area of Science:
- Oncology
- Medical Genetics
Background:
- Metastatic gastric cancer treatment relies on targeted therapies.
- Current targeted therapy selection is limited by biomarker understanding.
Purpose of the Study:
- To review advances in targeted therapies for metastatic gastric cancer.
- To highlight the importance of personalized biomarkers in treatment selection.
Main Methods:
- Literature review of current advances in targeted therapies.
- Analysis of the role of biomarkers in patient selection.
Main Results:
- HER2 overexpression is the only established predictive biomarker.
- Gastric tumors exhibit significant heterogeneity.
- Individual biomarkers are not fully elucidated but are key to effective therapy.
Conclusions:
- Personalized biomarker evaluation is paramount for improving outcomes in advanced gastric cancer.
- Understanding tumor heterogeneity is critical for novel therapeutic development.
- Optimizing patient selection based on biomarkers can enhance survival and reduce healthcare costs.
More Related Videos
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Mitogens and the Cell Cycle
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists